ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
09-01-2013
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
IBUPROFEN; METHOCARBAMOL
Fáanlegur frá:
TEVA CANADA LIMITED
ATC númer:
M03BA53
INN (Alþjóðlegt nafn):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Skammtar:
200MG; 500MG
Lyfjaform:
TABLET
Samsetning:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
18/40
Gerð lyfseðils:
OTC
Lækningarsvæði:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Vörulýsing:
Active ingredient group (AIG) number: 0248961001; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2021-08-12
Vara einkenni
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Lestu allt skjalið
